Details
New companies 3 · Follow-on 0
Stages: Series A 2, Series C+ 1
Mine $14M Series AOpenEvidence $250M Series DArena $150M Series ARecent funding activity in US startups, organised by investor and their role in each round.
New companies 3 · Follow-on 0
Stages: Series A 2, Series C+ 1
Mine $14M Series AOpenEvidence $250M Series DArena $150M Series ANew companies 3 · Follow-on 0
Stages: Series B 1, Series C+ 1, Undisclosed 1
Upwind Security $250M Series BSkild AI $1.4B UndisclosedOnebrief $200M Series DNew companies 3 · Follow-on 0
Stages: Series A 2, Undisclosed 1
Standard Nuclear $140M Series AUpscale AI $200M Series AHadrian Undisclosed UndisclosedNew companies 3 · Follow-on 0
Stages: Series C+ 2, Seed 1
Baseten $300M Series EOpenEvidence $250M Series DHumans& $480M SeedNew companies 3 · Follow-on 0
Stages: Series A 1, Series B 1, Undisclosed 1
Mendra $82M Series AFlywheel $27.5M UndisclosedCambium $100M Series BNew companies 3 · Follow-on 0
Stages: Series A 2, Series B 1
Mendra $82M Series AMirador Therapeutics $250M Series BAirNexis Therapeutics $200M Series ANew companies 3 · Follow-on 0
Stages: Series C+ 2, Undisclosed 1
OpenEvidence $250M Series DCyera $400M Series FAIR Control Concepts Undisclosed UndisclosedNew companies 3 · Follow-on 0
Stages: Series C+ 2, Undisclosed 1
OpenEvidence $250M Series DSkild AI $1.4B UndisclosedCyera $400M Series FNew companies 3 · Follow-on 0
Stages: Series B 2, Series A 1
Upscale AI $200M Series AEthernovia $90M Series BGSME $35M Series BNew companies 3 · Follow-on 0
Stages: Series A 2, Seed 1
Humans& $480M Seeddepthfirst $40M Series ACorgi Insurance $108M Series ANew companies 3 · Follow-on 0
Stages: Series C+ 2, Undisclosed 1
ClickHouse $400M Series DHadrian Undisclosed UndisclosedParabilis Medicines $305M Series FNew companies 3 · Follow-on 0
Stages: Pre-seed 1, Series A 1, Series B 1
RouteSense $2M Pre-SeedHydrosat $60M Series B and additional equityArray Labs $20M Series ANew companies 3 · Follow-on 0
Stages: Series C+ 2, Series B 1
Defense Unicorns $136M Series BOnebrief $200M Series DRain $250M Series CNew companies 3 · Follow-on 0
Stages: Series A 1, Series B 1, Series C+ 1
Mirador Therapeutics $250M Series BVizgen $48M Series AParabilis Medicines $305M Series FNew companies 2 · Follow-on 0
Stages: Pre-seed 1, Series A 1
Arkero $6M Pre-Seeddepthfirst $40M Series ANew companies 2 · Follow-on 0
Stages: Series B 2
Tenpoint Therapeutics $235M Series BKinaset Therapeutics $103M Series BNew companies 2 · Follow-on 0
Stages: Seed 1, Series A 1
Flying Tulip $25.5M Series ATenbin Labs $7M SeedNew companies 2 · Follow-on 0
Stages: Series A 2
Northslope $22M Series AValinor Enterprises $54M Series ANew companies 2 · Follow-on 0
Stages: Series A 2
Northslope $22M Series AValinor Enterprises $54M Series ANew companies 2 · Follow-on 0
Stages: Series A 1, Series C+ 1
Prenosis $20M Series AAntheia $24M Series C second closeNew companies 2 · Follow-on 0
Stages: Series A 2
Northslope $22M Series ACorgi Insurance $108M Series ANew companies 2 · Follow-on 0
Stages: Seed 1, Series A 1
Flying Tulip $25.5M Series ATenbin Labs $7M SeedNew companies 2 · Follow-on 0
Stages: Series B 1, Series C+ 1
Cellares $257M Series DZipline $600M Series B“—” in Led means every role for that investor in this period is undisclosed; it does not mean zero leads. New companies counts the first participation in a company in our records; follow-on counts later participation.